DLD Asset Management »

Lineage Cell Therapeutics In shares owned by DLD Asset Management

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by DLD Asset Management from 13F filings

Historical chart of DLD Asset Management investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by DLD Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by DLD Asset Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $33k 20k 1.67

More positions owned by DLD Asset Management

Echostar Corp Note 3.875%11/3 (Principal)
Stride Note 1.125% 9/0 (Principal)
Ormat Technologies Note 2.500% 7/1 (Principal)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ionis Pharmaceuticals Note 1.750% 6/1 (Principal)
Rivian Automotive Com Cl A Put Option (RIVN)
Progress Software Corp Note 1.000% 4/1 (Principal)
Transocean Deb 4.625% 9/3 (Principal)
Centrus Energy Corp Note 2.250%11/0 (Principal)
Bofa Fin MTNF 0.600% 5/2 (Principal)
Makemytrip Limited Mauritius Note 2/1 (Principal)
Advanced Energy Inds Note 2.500% 9/1 (Principal)
Wolfspeed Note 2.500% 6/1 (Principal)
Starwood Ppty Tr Note 6.750% 7/1 (Principal)
Cidara Therapeutics Com New Call Option (CDTX)

View all positions for DLD Asset Management

Top funds holding Lineage Cell Therapeutics In

Broadwood Capital
Vanguard Group
Defender Capital
Raffles Associates
Brian McDonald
BlackRock
Millennium Management
Geode Capital Management
Renaissance Technologies
Goldman Sachs Group
Marshall Wace
State Street Corporation
Jane Street
Susquehanna International
Red Crane Wealth Management

View all funds holding Lineage Cell Therapeutics In